Efficacy and Safety of Alpha-Pinene Supplementation on Markers in Patients with Type 2 Diabetes

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20121021011192N20

Enrollment

Registered

2025-08-25

Start date

2025-08-23

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with diagnosis of type 2 diabetes melitus. Diabetes mellitus due to underlying condition

Interventions

Intervention 1: Intervention group: receiving all necessary medications for treatment of diabetes type 2 on the basis of American diabetes association plus administration of250 mg/d alphapinen (ziran

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with diagnosis of type 2 diabetes melitus on the basis of clinical symptoms Obtaining written informed consent

Exclusion criteria

Exclusion criteria: Patients with previous history of allergy to herbal compounds

Design outcomes

Primary

Measure	Time frame
Change in amount of hemoglobin A1C. Timepoint: 60 days after addition of alphapinen. Method of measurement: Laboratory evaluation by enzymatic method.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Abbasinazari

Shahid Beheshti University of Medical Sciences

m_abbasi@sbmu.ac.ir+98 21 8887 3704

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026